Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 18/20 | 0.59 |
| ▸ | PTGS1 | P23219 | 15/20 | 0.59 |
| ▸ | CA1 | P00915 | 2/20 | 0.46 |
| ▸ | CA2 | P00918 | 2/20 | 0.46 |
| ▸ | CA9 | Q16790 | 2/20 | 0.46 |
| ▸ | CA4 | P22748 | 1/20 | 0.46 |
| ▸ | CA5A | P35218 | 1/20 | 0.46 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.46 |
| ▸ | CA12 | O43570 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8653126 | 0.87 | PTGS2 (0.67) | PTGS2PTGS1 | |
| Sulfamide SCHEMBL4638971 | 0.85 | PTGS2 (0.53) | PTGS2PTGS1 | |
| SCHEMBL7114365 | 0.83 | PTGS2 (0.56) | PTGS2PTGS1 | |
| SCHEMBL8384117 | 0.82 | PTGS2 (0.64) | PTGS2PTGS1 | |
| SCHEMBL8384163 | 0.82 | PTGS2 (0.60) | PTGS2PTGS1 | |
| SCHEMBL8652232 | 0.82 | PTGS2 (0.68) | PTGS2PTGS1CA2CA9CA12 | |
| SCHEMBL8651288 | 0.82 | PTGS2 (0.68) | PTGS2PTGS1CA2CA9CA12 | |
| SCHEMBL8385169 | 0.82 | PTGS2 (0.62) | PTGS2PTGS1 | |
| SCHEMBL8651784 | 0.82 | PTGS2 (0.55) | PTGS2PTGS1CA1CA2CA9 | |
| SCHEMBL8653101 | 0.81 | PTGS2 (0.69) | PTGS2PTGS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 367 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1479385-B1 | Use of cyclooxygenase-2 inhibitors in the treatment and prevention of neoplasia | SEARLE LLC (US) | 2008-07-02 | — | — | EP | claimed |
| CN-1332661-C | Methods of treating and preventing neoplasia using cyclooxygenase-2 inhibitors | SEARLE & CO (US) | 2007-08-22 | — | — | CN | claimed |
| CN-1767835-A | Compositions comprising cyclooxygenase-2 selective inhibitors and glucosamine for the treatment and prevention of pain and inflammation | PHARMACIA CORP (US) | 2006-05-03 | — | — | CN | claimed |
| EP-0843549-B1 | COMPOSITIONS COMPRISING A CYCLOOXYGENASE-2 INHIBITOR AND A LEUKOTRIENE A 4 HYDROLASE INHIBITOR | SEARLE & CO (US) | 2006-04-12 | — | — | EP | claimed |
| CN-1697654-A | Use of COx-2 inhibitors in combination with antiviral agents for the treatment of papilloma virus infections | UPJOHN CO (US) | 2005-11-16 | — | — | CN | claimed |
| EP-0833622-B8 | COMPOSITIONS COMPRISING A CYCLOOXYGENASE-2 INHIBITOR AND A 5-LIPOXYGENASE INHIBITOR | SEARLE & CO (US) | 2005-10-12 | — | — | EP | claimed |
| CN-1660083-A | Method of using benzenesulphoamides that are cyclooxygenase-2-inhibitors in the treatment and prevention of neoplasia | G D SIORL & CO (US) | 2005-08-31 | — | — | CN | claimed |
| EP-0833622-B1 | COMPOSITIONS COMPRISING A CYCLOOXYGENASE-2 INHIBITOR AND A 5-LIPOXYGENASE INHIBITOR | SEARLE & CO (US) | 2005-08-10 | — | — | EP | claimed |
| EP-1539142-A2 | USE OF AN AMYLOID BETA VACCINATION IN COMBINATION WITH A SELECTIVE COX-2 INHIBITOR FOR THE TREATMENT OF ALZHEIMER S DISEASE | Pharmacia Corporation (US) | 2005-06-15 | — | — | EP | claimed |
| EP-1536863-A1 | USE OF CYCLOOXYGENASE-2 SELECTIVE INHIBITORS AND THROMBOLYTIC AGENTS FOR THE TREATMENT OR PREVENTION OF A VASO-OCCLUSIVE EVENT | Pharmacia Corporation (US) | 2005-06-08 | — | — | EP | claimed |
| WO-1998016227-A9 | METHOD OF USING CYCLOOXYGENASE-2 INHIBITORS IN THE TREATMENT AND PREVENTION OF NEOPLASIA | — | 1998-07-30 | — | — | WO | claimed |
| WO-1998022101-A2 | METHOD OF USING CYCLOOXYGENASE-2 INHIBITORS AS ANTI-ANGIOGENIC AGENTS | G.D. SEARLE & CO. (US) | 1998-05-28 | — | — | WO | claimed |
| EP-0843549-A1 | COMPOSITIONS COMPRISING A CYCLOOXYGENASE-2 INHIBITOR AND A LEUKOTRIENE A 4? HYDROLASE INHIBITOR | G.D. SEARLE & CO. (US) | 1998-05-27 | — | — | EP | claimed |
| EP-0833622-A1 | COMPOSITIONS COMPRISING A CYCLOOXYGENASE-2 INHIBITOR AND A 5-LIPOXYGENASE INHIBITOR | G.D. SEARLE & CO. (US) | 1998-04-08 | — | — | EP | claimed |
| EP-0833664-A1 | COMBINATION OF A CYCLOOXYGENASE-2 INHIBITOR AND A LEUKOTRIENE B 4? RECEPTOR ANTAGONIST FOR THE TREATMENT OF INFLAMMATIONS | G.D. SEARLE & CO. (US) | 1998-04-08 | — | — | EP | claimed |
| WO-1996041645-A1 | COMBINATION OF A CYCLOOXYGENASE-2 INHIBITOR AND A LEUKOTRIENE B4 RECEPTOR ANTAGONIST FOR THE TREATMENT OF INFLAMMATIONS | G.D. SEARLE & CO. (US) | 1996-12-27 | — | — | WO | claimed |
| WO-1996041626-A1 | COMPOSITIONS COMPRISING A CYCLOOXYGENASE-2 INHIBITOR AND A 5-LIPOXYGENASE INHIBITOR | G.D. SEARLE & CO. (US) | 1996-12-27 | — | — | WO | claimed |
| WO-1996041625-A1 | COMPOSITIONS COMPRISING A CYCLOOXYGENASE-2 INHIBITOR AND A LEUKOTRIENE A4 HYDROLASE INHIBITOR | G.D. SEARLE & CO. (US) | 1996-12-27 | — | — | WO | claimed |
| EP-0724566-A1 | 1,2-DIARYLCYCLOPENTENYL COMPOUNDS FOR THE TREATMENT OF INFLAMMATION | G.D. SEARLE & CO. (US) | 1996-08-07 | — | — | EP | claimed |
| WO-1995011883-A1 | 1,2-DIARYLCYCLOPENTENYL COMPOUNDS FOR THE TREATMENT OF INFLAMMATION | G.D. SEARLE & CO. (US) | 1995-05-04 | — | — | WO | claimed |